Diabetic Gastroparesis News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results - GlobeNewswire (press release)



GlobeNewswire (press release)
 
Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results 
GlobeNewswire (press release)
The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers ...
Analysts Set Evoke Pharma Inc (EVOK) Target Price at $9.14 - The ... The Lincolnian Online
Evoke Pharma, Inc. (EVOK) Reaches $2.07 Yearly Low; Genomic ... Norman Weekly

all 6 news articles » 


2021 Gastroparesis Drugs Market: Technological Innovation, Opportunities, Regions, Manufacturers & Forecast - Facts of Week



2021 Gastroparesis Drugs Market: Technological Innovation, Opportunities, Regions, Manufacturers & Forecast 
Facts of Week
The ?Gastroparesis Drugs Market? report gives an intelligible understanding of the present market condition which includes of substantial and predictable upcoming keyword opportunities for the investors and new entrants. This Report provides key ...

and more » 


Evoke Pharma reveals its gastroparesis nasal spray is only effective in women - Proactive Investors UK



Proactive Investors UK
 
Evoke Pharma reveals its gastroparesis nasal spray is only effective in women 
Proactive Investors UK
Evoke Pharma Inc (NASDAQ:EVOK) was one of the top fallers on the major US indexes after it confirmed that its Gimoti gastroparesis treatment is only effective in women. The Solana Beach, California-based company said it will file a new drug application ...
Evoke's planned FDA submission for Gimoti extended to next quarter; shares down 11% on women-only indication Seeking Alpha
Evoke Pharma (NASDAQ:EVOK) Rating Increased to Hold at Zacks ... Dispatch Tribunal
Evoke Pharma (NASDAQ:EVOK) Earning Somewhat Positive Press ... The Ledger Gazette
BZ Weekly  -Week Herald  -Reurope 
all 20 news articles » 


What is gastroparesis and how can it be treated? - Philly.com



Philly.com
 
What is gastroparesis and how can it be treated? 
Philly.com
For gastroparesis patients, eating a salad may make them feel like they are eating cement, which means that food is providing little nutrition for them. Juice 'em or Soup 'em . So if you can't eat fruits and veggies, what is the easiest way to get ...

 


Evoke Pharma (EVOK) Upgraded to ?Hold? at Zacks Investment Research - Week Herald



Week Herald
 
Evoke Pharma (EVOK) Upgraded to ?Hold? at Zacks Investment Research 
Week Herald
Evoke Pharma logo Evoke Pharma (NASDAQ:EVOK) was upgraded by Zacks Investment Research from a ?sell? rating to a ?hold? rating in a research report issued on Tuesday, February 6th. According to Zacks, ?Evoke Pharma, Inc. is a specialty pharmaceutical ...
Evoke Pharma, Inc. (EVOK) Reaches $2.03 After 7.00% Down Move; COSMO PHARMACEUTICALS NV ORDINARY ... UtahHerald.com

all 5 news articles » 


Evoke Announces Discovery of Sex-Based Pharmacokinetic ... - GlobeNewswire (press release)



GlobeNewswire (press release)
 
Evoke Announces Discovery of Sex-Based Pharmacokinetic ... 
GlobeNewswire (press release)
SOLANA BEACH, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced additional findings from its comparative exposure ...

and more » 


Gastroparesis Drugs Market Projected to Reach $6,486 Million at a ... - Chicago Evening Post



Gastroparesis Drugs Market Projected to Reach $6,486 Million at a ... 
Chicago Evening Post
Portland, OR ? 02/16/2018 ? The global gastroparesis market was valued at $4,667 million in 2016, and is projected to reach $6,486 million at a CAGR of 4.7% from 2017 to 2023. Gastroparesis is a medical condition of the stomach, which affects the ...

and more » 


EPS for Evoke Pharma, Inc. (EVOK) Expected At $-0.22; Watts Water Technologies (WTS)'s Sentiment Is 1.15 - UtahHerald.com



UtahHerald.com
 
EPS for Evoke Pharma, Inc. (EVOK) Expected At $-0.22; Watts Water Technologies (WTS)'s Sentiment Is 1.15 
UtahHerald.com
Analysts expect Evoke Pharma, Inc. (NASDAQ:EVOK) to report $-0.22 EPS on March, 21.They anticipate $0.04 EPS change or 22.22% from last quarter's $-0.18 EPS. After having $-0.24 EPS previously, Evoke Pharma, Inc.'s analysts see -8.33% EPS growth. The ...

and more » 


Diabetic Gastroparesis Market Epidemiology Outlining, Changing Trends, 7mm Coverage and Forecast 2027 - The Columnist



Diabetic Gastroparesis Market Epidemiology Outlining, Changing Trends, 7mm Coverage and Forecast 2027 
The Columnist
Diabetic Gastroparesis Market ? Epidemiology Forecast, 2027 comprises of extensive primary research along with the detailed analysis by qualitative as well as quantitative aspects of Diabetic Gastroparesis Market epidemiology providing the historical ...

and more » 


Significant Information on Diabetic Gastroparesis Treatment Market ... - MilTech



Significant Information on Diabetic Gastroparesis Treatment Market ... 
MilTech
The report titled, ?Global Diabetic Gastroparesis Treatment Market Report 2018,? has been recently added to its far-reaching repository in order to detail the key areas of the industry in a comprehensive manner. During their study of the market, the ...

and more »